KOD News and Press, Kodiak Sciences Inc From 10/01/22

The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event. For further details see: Kodiak Sciences (KOD) Presents at the 22nd Euretina Congress - Slideshow

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference PR Newswire PALO ALTO, Calif. , Sept. 7, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializ...

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACO...

Summary Our US-denominated Global Micro Fund was down 16.6% in the quarter, and is down 21.0% for the year. We are taking advantage of the current turmoil in the markets, adding a new busted Biotech (KOD), and adding substantially to MEI Pharma and Liberty Tripadvisor - among othe...

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO) PR Newswire PALO ALTO, Calif. , Aug. 18, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceu...

Kodiak Sciences press release ( NASDAQ: KOD ): Q2 GAAP EPS of -$1.74 beats by $0.02 . Kodiak ended the second quarter of 2022 with $597.9M of cash, cash equivalents and marketable securities. For further details see: Kodiak Sciences GAAP EPS of -$1.74 beats b...

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Aug. 9, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developin...

Kodiak Sciences is a biotech company looking to improve standard of care in different eye indications. In February 2022, the stock had sold off 80% on a Phase 2b/3 failure, and never recovered. Kodiak Sciences now reported meeting the primary endpoint in its Phase 3 Beacon trial i...

The clinical-stage biotech Kodiak Sciences ( NASDAQ: KOD ) jumped ~15% in the morning hours Monday after the company said its BEACON Phase 3 study for lead asset tedromer met the primary endpoint in patients with macular edema due to retinal vein occlusion. The global trial invo...